BD Launches First and Only Fully Sterile Povidone-Iodine and Isopropyl Alcohol Skin Preparation

FRANKLIN LAKES, N.J., July 7, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the availability of BD PurPrep™ patient preoperative skin preparation with sterile solution, the first and only fully sterile povidone-iodine plus isopropyl alcohol single-use antiseptic skin preparation (PVP-I; 0.83% available iodine and 72.5% isopropyl alcohol) commercially available in the United States.

BD PurPrep™ joins BD ChloraPrep™ patient preoperative skin preparation as the only fully sterile skin preparations available on the market that use a single-use applicator specifically designed to prevent cross-contamination and promote aseptic non-touch technique. The BD PurPrep™ patient preoperative skin preparation is an effective skin preparation alternative when the use of a chlorhexidine gluconate (CHG/IPA) is contraindicated or the patient is sensitive to CHG.

Donald E. Fry, M.D., a nationally recognized expert in infection prevention. “Sterile single-use products have been shown to reduce the risk of outbreaks linked to microbial contamination of antiseptic products. By developing fully sterile PurPrep and ChloraPrep, BD is providing health care professionals with a more complete set of tools to reduce the risk of intrinsic contamination in antiseptic solutions.”

Michael Cusack, BD, Vice President/General Manager of Infection Prevention. “By adding a non-CHG, fully sterile skin preparation option, BD is expanding the number of tools available to help reduce the risk of infection in patients with CHG sensitivities and during procedures when CHG/IPA is not indicated.”

More:  SHAREHOLDER ALERT: HPQ BDX XP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

BD PurPrep™ will replace Prevail™ and Prevail FX™, and is available now through BD and other distribution partners.

Like BD ChloraPrep™, the new BD PurPrep™ sterile solution will include a mark to indicate that the solution is sterile. Though not required by the U.S. Food and Drug Administration (FDA), BD developed this mark to distinguish sterile solutions from non-sterile antiseptic skin preparations. In 2013, the FDA asked manufacturers to voluntarily change labeling on products (sterile vs. non-sterile) to further educate customers on the issue.

More:  BD, Babson Diagnostics Announce Strategic Partnership Agreement to Enable Small-Volume Blood Collection for Diagnostic Testing in Retail Settings


Troy Kirkpatrick  

Monique Dolecki

BD Public Relations   

BD Investor Relations




1Jeng, D. A new, water-resistant, film-forming, 30-second, one-step application iodophor preoperative skin preparation. Am J Infect Control. 2001, 29(6):370-376

2Mashiatulla, M. (2020). Iodine-based Pre-Operative Skin Preparation Product Performance on Porcine Abdominal Skin. Internal BD report: unpublished.


Cision” data-reactid=”78″>View original content to download multimedia:

SOURCE BD (Becton, Dickinson and Company)

More from: | Category: Medical Device Company News